Palmatine

Palmatine's sedative properties appear mediated through dopamine biosynthesis inhibition (IC50 = 7.9 μM in PC12 cells) and alpha-2 adrenergic receptor binding (IC50 = 956 nM), rather than direct GABA-A modulation — a 2003 study found palmatine had no effect on GABA-A binding, unlike its reduced derivative tetrahydropalmatine. Palmatine crosses the blood-brain barrier, enabling CNS activity. Evidence is limited to in vitro receptor/enzyme studies.

In vitro studies demonstrate palmatine has antimicrobial activity via DNA intercalation, DNA synthesis inhibition, and reverse transcriptase inhibition. Showed in vitro antimalarial potency comparable to quinine against P. falciparum, but completely failed to translate in vivo in mice, likely due to poor oral bioavailability (<10%). Antibacterial and antiviral properties confirmed in review but with limited standalone evidence.

A comprehensive review identifies palmatine as anti-inflammatory via NF-κB pathway inhibition. In a Mahonia oiwakensis extract study (containing palmatine, berberine, and jatrorrhizine), the extract reduced inflammatory markers and pain responses in mice. However, effects cannot be definitively attributed to palmatine alone given multi-alkaloid composition of studied extracts.

In CCl4-treated rats, a Mahonia oiwakensis extract containing palmatine decreased serum ALT and AST at 100 and 500 mg/kg. An earlier study showed protoberberine alkaloids including palmatine from Enantia chlorantha had hepatoprotective effects in thioacetamide-injured rat liver. Both studies used multi-alkaloid extracts, limiting attribution to palmatine specifically.

In diabetic KK-Ay mice, palmatine decreased fasting blood glucose and improved glucose tolerance alongside other Coptidis Rhizoma alkaloids. In vitro glucose consumption was also increased in HepG2 cells. Effects were weaker than berberine. No human data exist.

In isolated rat distal colon tissue, palmatine inhibited both Ca2+-activated (IC50 ~24 μM, maximal inhibition ~85%) and cAMP-activated (IC50 ~62 μM) chloride secretion pathways via blockade of SK4 K+ channels, CFTR Cl- channels, and KvLQT1 K+ channels. This dual anti-secretory mechanism supports traditional use of berberine-containing plants for diarrhea.

In PC12 cells, palmatine reduced dopamine content by 61% at 20 μM (IC50 = 7.9 μM), more potently than berberine (53.7% reduction, IC50 = 18.6 μM). The mechanism involves direct inhibition of tyrosine hydroxylase enzyme activity rather than gene expression regulation. This dopaminergic modulation may underlie sedative properties but also raises concerns about dopamine depletion.